Seer, Inc. (SEER) Misses Q4 EPS by 6c, Revenues Beat

Seer, Inc. (NASDAQ: SEER) reported Q4 EPS of ($0.54), $0.06 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $336 thousand versus the consensus estimate of $100 thousand.

“I am extremely proud of the progress we have made to date and the enthusiasm in the market surrounding our Proteograph™ Product Suite,” said Omid Farokhzad, Chair and Chief Executive Officer. “Since January, we have brought on two new collaboration customers, signed three commercial agreements, and entered the second phase of our commercialization plan. We, along with our partners and collaborators, have presented exciting data generated from our platform at four different scientific conferences so far this year. The emerging data using the Proteograph Product Suite is giving glimpses of the vast undiscovered proteomic information that only unbiased, deep studies can begin to unlock. Seer is uniquely positioned to transform access to the proteome, empower our customers to make novel discoveries, and enable them to have a profound impact on science and medicine.”

For earnings history and earnings-related data on Seer, Inc. (SEER) click here.

You May Also Be Interested In

• Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening
• Ferrari names new chief marketing officer, effective July 2026
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity